Research graph
References from Beyond poly(ADP-ribose) polymerase inhibition: emerging therapeutic strategies for germline BRCA1/2-mutated and PALB2-mutated breast cancers. Local targets link to admitted publications; unresolved targets remain external evidence.
Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
10.1001/jama.2017.7112 · 2017 · External reference
Breast-cancer risk in families with mutations in PALB2
10.1056/nejmoa1400382 · 2014 · External reference
A population-based study of genes previously implicated in breast cancer
10.1056/nejmoa2005936 · 2021 · External reference
BRCA1- and BRCA2-associated hereditary breast and ovarian cancer
1993 · External reference
BRCA1 and BRCA2: different roles in a common pathway of genome protection
10.1038/nrc3181 · 2011 · External reference
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
10.1038/nature03445 · 2005 · External reference
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
10.1038/nature03443 · 2005 · External reference
PARP inhibitors for breast cancer treatment: a review
10.1001/jamaoncol.2023.7322 · 2024 · External reference
PARP inhibitors: enhancing efficacy through rational combinations
10.1038/s41416-023-02326-7 · 2023 · External reference
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation
10.1056/nejmoa1706450 · 2017 · External reference
Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer
10.1056/nejmoa2105215 · 2021 · External reference
Talazoparib in patients with advanced breast cancer and a germline BRCA mutation
10.1056/nejmoa1802905 · 2018 · External reference
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: phase II study of olaparib monotherapy for patients with metastatic breast cancer with germline mutations in PALB2 or somatic mutations in BRCA1 or BRCA2
10.1200/jco-25-02075 · 2026 · External reference
Homologous recombination deficiency landscape of breast cancers and real-world effectiveness of poly ADP-ribose polymerase inhibitors in patients with somatic BRCA1/2, germline PALB2, or homologous recombination deficiency signature
2023 · External reference
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials
10.1016/j.ygyno.2021.03.011 · 2021 · External reference
PARP inhibitor resistance: the underlying mechanisms and clinical implications
10.1186/s12943-020-01227-0 · 2020 · External reference
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
10.1038/s41571-021-00532-x · 2021 · External reference
Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance
10.1158/2159-8290.cd-19-1485 · 2020 · External reference
Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer
10.1158/1078-0432.ccr-17-0544 · 2017 · External reference
Resistance to therapy caused by intragenic deletion in BRCA2
10.1038/nature06548 · 2008 · External reference
Replication fork stability confers chemoresistance in BRCA-deficient cells
10.1038/nature18325 · 2016 · External reference
Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD
10.1016/j.annonc.2021.08.2154 · 2021 · External reference
Determinants of response to talazoparib in patients with HER2-negative, germline BRCA1/2-mutated breast cancer
10.1158/1078-0432.ccr-21-2080 · 2022 · External reference
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
10.1093/annonc/mdy099 · 2018 · External reference
Abstract RF5-05: predicting olaparib sensitivity in patients with metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations according to their homologous recombination status by the RAD51 test: primary analysis of the RADIOLA phase II trial
10.1158/1557-3265.sabcs25-rf5-05 · 2026 · External reference
Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer
10.1158/1078-0432.ccr-22-3715 · 2023 · External reference
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
10.1056/nejmoa0900212 · 2009 · External reference
PARP1 tyrapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow
10.1158/1541-7786.mcr-18-0138 · 2019 · External reference
Parp-2 is required to maintain hematopoiesis following sublethal (-irradiation in mice
10.1182/blood-2012-12-472845 · 2013 · External reference
PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors
10.1038/cdd.2014.202 · 2015 · External reference
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
10.1186/s13073-024-01370-z · 2024 · External reference
Leslie M Next-Gen PARP inhibitor effective in breast cancer
2024 · External reference
Abstract PS1-10-28: phase 1/2a trial of new generation PARP1-selective inhibitor saruparib + next generation selective ER degrader (SERD) camizestrant in patients (pts) with advanced/relapsed ER+/HER2-negative or low (HER2−) breast cancer (PETRA Module 6)
10.1158/1557-3265.sabcs25-ps1-10-28 · 2026 · External reference
923MO first results from a phase I trial of SNV1521, a next generation, CNS-penetrant, PARP1-selective inhibitor in patients (pts) with molecularly selected advanced solid tumors
10.1016/j.annonc.2025.08.1492 · 2025 · External reference
Targeting PARP1: a promising approach for next-generation poly (ADP-ribose) polymerase inhibitors
10.1007/s12609-025-00582-5 · 2025 · External reference
Impact of BRCA mutation on treatment outcomes of endocrine therapy ± CDK4/6 inhibitors in hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancer: a systematic review and meta-analysis
10.1200/po-24-00841 · 2025 · External reference
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer
10.1038/s41586-026-10197-0 · 2026 · External reference
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
10.1038/s43018-024-00893-z · 2025 · External reference
Modification of the DNA damage response by therapeutic CDK4/6 inhibition
10.1074/jbc.m112.365494 · 2012 · External reference
CDK4/6i reverse PARPi resistance by targeting the E2F1- MCM2/5 pathway
2026 · External reference
Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells
10.1007/s00210-022-02375-4 · 2023 · External reference
Abstract PS4-39: efficacy of combined CDK4/6 inhibitor and PARP inhibitor in the treatment of BRCA1 mutant triple negative breast cancer
10.1158/1538-7445.sabcs20-ps4-39 · 2021 · External reference
A novel CDK4/6 and PARP dual inhibitor ZC-22 effectively suppresses tumor growth and improves the response to cisplatin treatment in breast and ovarian cancer
10.3390/ijms23052892 · 2022 · External reference
Discovery of selective PARP1/CDK6 dual target inhibitors modulating Wnt signaling pathway for the treatment of TNBC
10.1016/j.bioorg.2026.109698 · 2026 · External reference
Abstract CT047: phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
2017 · External reference
HOPE: harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer
10.1200/jco.2024.42.16_suppl.10616 · 2024 · External reference
Antibody-drug conjugates in breast cancer: current status and future directions
10.3390/ijms241813726 · 2023 · External reference
Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor-positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)
10.1200/jco.2025.43.16_suppl.1013 · 2025 · External reference
432P Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptor-positive metastatic breast cancer in DESTINY-Breast04
10.1016/j.annonc.2024.08.379 · 2024 · External reference
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
10.1016/j.annonc.2021.06.002 · 2021 · External reference
Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study
10.1200/jco.2024.42.16_suppl.1075 · 2024 · External reference
Design and preclinical evaluation of a novel B7-H4-directed antibody-drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305
10.1158/1078-0432.ccr-22-2630 · 2023 · External reference
SN-38 sensitizes BRCA-proficient ovarian cancers to PARP inhibitors through inhibiting homologous recombination repair
10.1155/2022/7243146 · 2022 · External reference
Advancing antibody-drug conjugates: current perspectives and future directions
10.1200/edbk-26-517110 · 2026 · External reference
Beyond DNA repair: the novel immunological potential of PARP inhibitors
10.1080/23723556.2019.1585170 · 2019 · External reference
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
10.1016/j.celrep.2018.11.054 · 2018 · External reference
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
10.1001/jamaoncol.2019.1029 · 2019 · External reference
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
10.1016/s1470-2045(20)30324-7 · 2020 · External reference
Abstract RF5-03: OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer
10.1158/1557-3265.sabcs25-rf5-03 · 2026 · External reference
Abstract RF3-01: TBCRC 056: a phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the ER+/HER2- cohort
10.1158/1557-3265.sabcs24-rf3-01 · 2025 · External reference
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
10.1056/nejmoa1813904 · 2019 · External reference
Capivasertib in hormone receptor-positive advanced breast cancer
10.1056/nejmoa2214131 · 2023 · External reference
Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer
10.1056/nejmoa2404625 · 2024 · External reference
Negative Regulation of AKT Activation by BRCA1
10.1158/0008-5472.can-08-3009 · 2008 · External reference
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer
10.1158/2159-8290.cd-11-0336 · 2012 · External reference
Role of Akt activation in PARP inhibitor resistance in cancer
10.3390/cancers12030532 · 2020 · External reference
PARP inhibitors resistance: mechanisms and perspectives
10.3390/cancers14061420 · 2022 · External reference
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
10.1093/annonc/mdw672 · 2017 · External reference
Phase 1b clinical trial with alpelisib plus olaparib for patients with advanced triple-negative breast cancer
10.1158/1078-0432.ccr-21-3045 · 2022 · External reference
Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2- and non-BRCA1/2-mutant cancers
10.1158/2159-8290.cd-20-0163 · 2020 · External reference
Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers
10.1007/s10549-025-07747-x · 2025 · External reference
New horizons of synthetic lethality in cancer: current development and future perspectives
10.1021/acs.jmedchem.4c00113 · 2024 · External reference
Essential roles for polymerase θ-mediated end joining in the repair of chromosome breaks
10.1016/j.molcel.2016.06.020 · 2016 · External reference
Development of synthetic lethality in cancer: molecular and cellular classification
10.1038/s41392-020-00358-6 · 2020 · External reference
Genetic determinants of cellular addiction to DNA polymerase theta
10.1038/s41467-019-12234-1 · 2019 · External reference
924MO First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors
10.1016/j.annonc.2025.08.1493 · 2025 · External reference
Emerging strategies for cancer therapy by ATR inhibitors
10.1111/cas.15845 · 2023 · External reference
Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog
10.1016/0092-8674(87)90458-2 · 1987 · External reference
ATR prohibits replication catastrophe by preventing global exhaustion of RPA
10.1016/j.cell.2013.10.043 · 2013 · External reference
Targeting WEE1 kinase in cancer
10.1016/j.tips.2016.06.006 · 2016 · External reference
Coupling of homologous recombination and the checkpoint by ATR
10.1016/j.molcel.2016.12.007 · 2017 · External reference
PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1
10.1038/s41467-020-14563-y · 2020 · External reference
Results from plasmaMATCH trial cohort E: a phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010)
10.1200/jco.2022.40.16_suppl.1024 · 2022 · External reference
161O VIOLETTE: randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC)
10.1016/j.annonc.2022.03.180 · 2022 · External reference
Abstract PO4-16-01: EZH2 is overexpressed in invasive carcinoma and DCIS in both BRCA1 and BRCA2 mutation carriers
10.1158/1538-7445.sabcs23-po4-16-01 · 2024 · External reference
The TIP60-ATM axis regulates replication fork stability in BRCA-deficient cells
10.1038/s41389-022-00410-w · 2022 · External reference
EZH2 directly methylates PARP1 and regulates its activity in cancer
10.1126/sciadv.adl2804 · 2024 · External reference
The mitochondrial translocation of phosphorylated EZH2 promotes PARP inhibitor resistance in BRCA1-deficient epithelial ovarian cancer
10.1038/s41421-026-00880-x · 2026 · External reference
Cooperation of the ATM and Fanconi anemia/BRCA pathways in double-strand break end resection
10.1016/j.celrep.2020.01.052 · 2020 · External reference
Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
10.1001/jama.2017.7112 · ExternalCitation · doi-reference
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
10.1001/jamaoncol.2019.1029 · ExternalCitation · doi-reference
PARP inhibitors for breast cancer treatment: a review
10.1001/jamaoncol.2023.7322 · ExternalCitation · doi-reference
Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells
10.1007/s00210-022-02375-4 · ExternalCitation · doi-reference
Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers
10.1007/s10549-025-07747-x · ExternalCitation · doi-reference
Targeting PARP1: a promising approach for next-generation poly (ADP-ribose) polymerase inhibitors
10.1007/s12609-025-00582-5 · ExternalCitation · doi-reference
Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog
10.1016/0092-8674(87)90458-2 · ExternalCitation · doi-reference
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
10.1016/j.annonc.2021.06.002 · ExternalCitation · doi-reference
Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD
10.1016/j.annonc.2021.08.2154 · ExternalCitation · doi-reference
161O VIOLETTE: randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC)
10.1016/j.annonc.2022.03.180 · ExternalCitation · doi-reference
432P Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptor-positive metastatic breast cancer in DESTINY-Breast04
10.1016/j.annonc.2024.08.379 · ExternalCitation · doi-reference
923MO first results from a phase I trial of SNV1521, a next generation, CNS-penetrant, PARP1-selective inhibitor in patients (pts) with molecularly selected advanced solid tumors
10.1016/j.annonc.2025.08.1492 · ExternalCitation · doi-reference
924MO First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors
10.1016/j.annonc.2025.08.1493 · ExternalCitation · doi-reference
Discovery of selective PARP1/CDK6 dual target inhibitors modulating Wnt signaling pathway for the treatment of TNBC
10.1016/j.bioorg.2026.109698 · ExternalCitation · doi-reference
ATR prohibits replication catastrophe by preventing global exhaustion of RPA
10.1016/j.cell.2013.10.043 · ExternalCitation · doi-reference
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
10.1016/j.celrep.2018.11.054 · ExternalCitation · doi-reference
Cooperation of the ATM and Fanconi anemia/BRCA pathways in double-strand break end resection
10.1016/j.celrep.2020.01.052 · ExternalCitation · doi-reference
Essential roles for polymerase θ-mediated end joining in the repair of chromosome breaks
10.1016/j.molcel.2016.06.020 · ExternalCitation · doi-reference
Coupling of homologous recombination and the checkpoint by ATR
10.1016/j.molcel.2016.12.007 · ExternalCitation · doi-reference
Targeting WEE1 kinase in cancer
10.1016/j.tips.2016.06.006 · ExternalCitation · doi-reference
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials
10.1016/j.ygyno.2021.03.011 · ExternalCitation · doi-reference
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
10.1016/s1470-2045(20)30324-7 · ExternalCitation · doi-reference
New horizons of synthetic lethality in cancer: current development and future perspectives
10.1021/acs.jmedchem.4c00113 · ExternalCitation · doi-reference
PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors
10.1038/cdd.2014.202 · ExternalCitation · doi-reference
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
10.1038/nature03443 · ExternalCitation · doi-reference
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
10.1038/nature03445 · ExternalCitation · doi-reference
Resistance to therapy caused by intragenic deletion in BRCA2
10.1038/nature06548 · ExternalCitation · doi-reference
Replication fork stability confers chemoresistance in BRCA-deficient cells
10.1038/nature18325 · ExternalCitation · doi-reference
BRCA1 and BRCA2: different roles in a common pathway of genome protection
10.1038/nrc3181 · ExternalCitation · doi-reference
The TIP60-ATM axis regulates replication fork stability in BRCA-deficient cells
10.1038/s41389-022-00410-w · ExternalCitation · doi-reference
Development of synthetic lethality in cancer: molecular and cellular classification
10.1038/s41392-020-00358-6 · ExternalCitation · doi-reference
PARP inhibitors: enhancing efficacy through rational combinations
10.1038/s41416-023-02326-7 · ExternalCitation · doi-reference
The mitochondrial translocation of phosphorylated EZH2 promotes PARP inhibitor resistance in BRCA1-deficient epithelial ovarian cancer
10.1038/s41421-026-00880-x · ExternalCitation · doi-reference
Genetic determinants of cellular addiction to DNA polymerase theta
10.1038/s41467-019-12234-1 · ExternalCitation · doi-reference
PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1
10.1038/s41467-020-14563-y · ExternalCitation · doi-reference
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
10.1038/s41571-021-00532-x · ExternalCitation · doi-reference
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer
10.1038/s41586-026-10197-0 · ExternalCitation · doi-reference
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
10.1038/s43018-024-00893-z · ExternalCitation · doi-reference
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
10.1056/nejmoa0900212 · ExternalCitation · doi-reference
Breast-cancer risk in families with mutations in PALB2
10.1056/nejmoa1400382 · ExternalCitation · doi-reference
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation
10.1056/nejmoa1706450 · ExternalCitation · doi-reference
Talazoparib in patients with advanced breast cancer and a germline BRCA mutation
10.1056/nejmoa1802905 · ExternalCitation · doi-reference
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
10.1056/nejmoa1813904 · ExternalCitation · doi-reference
A population-based study of genes previously implicated in breast cancer
10.1056/nejmoa2005936 · ExternalCitation · doi-reference
Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer
10.1056/nejmoa2105215 · ExternalCitation · doi-reference
Capivasertib in hormone receptor-positive advanced breast cancer
10.1056/nejmoa2214131 · ExternalCitation · doi-reference
Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer
10.1056/nejmoa2404625 · ExternalCitation · doi-reference
Modification of the DNA damage response by therapeutic CDK4/6 inhibition
10.1074/jbc.m112.365494 · ExternalCitation · doi-reference
Beyond DNA repair: the novel immunological potential of PARP inhibitors
10.1080/23723556.2019.1585170 · ExternalCitation · doi-reference
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
10.1093/annonc/mdw672 · ExternalCitation · doi-reference
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
10.1093/annonc/mdy099 · ExternalCitation · doi-reference
Emerging strategies for cancer therapy by ATR inhibitors
10.1111/cas.15845 · ExternalCitation · doi-reference
EZH2 directly methylates PARP1 and regulates its activity in cancer
10.1126/sciadv.adl2804 · ExternalCitation · doi-reference
SN-38 sensitizes BRCA-proficient ovarian cancers to PARP inhibitors through inhibiting homologous recombination repair
10.1155/2022/7243146 · ExternalCitation · doi-reference
Negative Regulation of AKT Activation by BRCA1
10.1158/0008-5472.can-08-3009 · ExternalCitation · doi-reference
Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer
10.1158/1078-0432.ccr-17-0544 · ExternalCitation · doi-reference
Determinants of response to talazoparib in patients with HER2-negative, germline BRCA1/2-mutated breast cancer
10.1158/1078-0432.ccr-21-2080 · ExternalCitation · doi-reference
Phase 1b clinical trial with alpelisib plus olaparib for patients with advanced triple-negative breast cancer
10.1158/1078-0432.ccr-21-3045 · ExternalCitation · doi-reference
Design and preclinical evaluation of a novel B7-H4-directed antibody-drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305
10.1158/1078-0432.ccr-22-2630 · ExternalCitation · doi-reference
Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer
10.1158/1078-0432.ccr-22-3715 · ExternalCitation · doi-reference
Abstract PS4-39: efficacy of combined CDK4/6 inhibitor and PARP inhibitor in the treatment of BRCA1 mutant triple negative breast cancer
10.1158/1538-7445.sabcs20-ps4-39 · ExternalCitation · doi-reference
Abstract PO4-16-01: EZH2 is overexpressed in invasive carcinoma and DCIS in both BRCA1 and BRCA2 mutation carriers
10.1158/1538-7445.sabcs23-po4-16-01 · ExternalCitation · doi-reference
PARP1 tyrapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow
10.1158/1541-7786.mcr-18-0138 · ExternalCitation · doi-reference
Abstract RF3-01: TBCRC 056: a phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the ER+/HER2- cohort
10.1158/1557-3265.sabcs24-rf3-01 · ExternalCitation · doi-reference
Abstract PS1-10-28: phase 1/2a trial of new generation PARP1-selective inhibitor saruparib + next generation selective ER degrader (SERD) camizestrant in patients (pts) with advanced/relapsed ER+/HER2-negative or low (HER2−) breast cancer (PETRA Module 6)
10.1158/1557-3265.sabcs25-ps1-10-28 · ExternalCitation · doi-reference
Abstract RF5-03: OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer
10.1158/1557-3265.sabcs25-rf5-03 · ExternalCitation · doi-reference
Abstract RF5-05: predicting olaparib sensitivity in patients with metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations according to their homologous recombination status by the RAD51 test: primary analysis of the RADIOLA phase II trial
10.1158/1557-3265.sabcs25-rf5-05 · ExternalCitation · doi-reference
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer
10.1158/2159-8290.cd-11-0336 · ExternalCitation · doi-reference
Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance
10.1158/2159-8290.cd-19-1485 · ExternalCitation · doi-reference
Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2- and non-BRCA1/2-mutant cancers
10.1158/2159-8290.cd-20-0163 · ExternalCitation · doi-reference
Parp-2 is required to maintain hematopoiesis following sublethal (-irradiation in mice
10.1182/blood-2012-12-472845 · ExternalCitation · doi-reference
PARP inhibitor resistance: the underlying mechanisms and clinical implications
10.1186/s12943-020-01227-0 · ExternalCitation · doi-reference
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
10.1186/s13073-024-01370-z · ExternalCitation · doi-reference
Advancing antibody-drug conjugates: current perspectives and future directions
10.1200/edbk-26-517110 · ExternalCitation · doi-reference
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: phase II study of olaparib monotherapy for patients with metastatic breast cancer with germline mutations in PALB2 or somatic mutations in BRCA1 or BRCA2
10.1200/jco-25-02075 · ExternalCitation · doi-reference
Results from plasmaMATCH trial cohort E: a phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010)
10.1200/jco.2022.40.16_suppl.1024 · ExternalCitation · doi-reference
HOPE: harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer
10.1200/jco.2024.42.16_suppl.10616 · ExternalCitation · doi-reference
Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study
10.1200/jco.2024.42.16_suppl.1075 · ExternalCitation · doi-reference
Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor-positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)
10.1200/jco.2025.43.16_suppl.1013 · ExternalCitation · doi-reference
Impact of BRCA mutation on treatment outcomes of endocrine therapy ± CDK4/6 inhibitors in hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancer: a systematic review and meta-analysis
10.1200/po-24-00841 · ExternalCitation · doi-reference
Role of Akt activation in PARP inhibitor resistance in cancer
10.3390/cancers12030532 · ExternalCitation · doi-reference
PARP inhibitors resistance: mechanisms and perspectives
10.3390/cancers14061420 · ExternalCitation · doi-reference
A novel CDK4/6 and PARP dual inhibitor ZC-22 effectively suppresses tumor growth and improves the response to cisplatin treatment in breast and ovarian cancer
10.3390/ijms23052892 · ExternalCitation · doi-reference
Antibody-drug conjugates in breast cancer: current status and future directions
10.3390/ijms241813726 · ExternalCitation · doi-reference
